Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alectinib is a novel anaplastic lymphoma kinase (ALK) inhibitor for treatment of patients with ALK-positive non-small-cell lung cancer who have progressed on or are intolerant to crizotinib. To support clinical development, concentrations of alectinib and metabolite M4 were determined in plasma from patients and healthy subjects.

          Related collections

          Author and article information

          Journal
          Bioanalysis
          Bioanalysis
          Future Science, LTD
          1757-6199
          1757-6180
          Jul 2016
          : 8
          : 14
          Affiliations
          [1 ] Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
          [2 ] Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara Kamakura Kanagawa, 247-8530 Japan.
          [3 ] Roche Pharmaceutical Research & Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, 430 East 29th Street, New York, NY 10016, USA.
          Article
          10.4155/bio-2016-0068
          27329641

          Comments

          Comment on this article